Urokinase
- Generic Name
- Urokinase
- Brand Names
- Kinlytic
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9039-53-6
- Unique Ingredient Identifier
- 83G67E21XI
- Background
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond.
Urokinase was granted FDA approval on 16 January 1978.
- Indication
In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.
- Associated Conditions
- Obstruction; Catheter, Infusion Catheter (Vascular), Pulmonary Embolism, Pulmonary Embolism Acute Massive, Thromboembolism of the Coronary Artery, Thromboembolism of the Graft, Thromboembolism of the Peripheral Artery
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath